Featuring Dr Courtney D DiNardo’s perspectives on her time spent
speaking with patients with acute myeloid leukemia from the
practices of community oncologists Drs KS Kumar and Andrew C
Rettew, including the following topics:
Case: A woman in her early 70s with acute myeloid leukemia
(AML) and an IDH mutation receives venetoclax and azacytidine
(0:00)
Selection of patients for treatment with venetoclax/azacitidine
versus intensive 7 + 3 chemotherapy; optimal application of
venetoclax/azacytidine (5:41)
Tolerability and side effects of venetoclax/azacitidine;
testing for IDH mutations and choice of therapy for patients with
AML and an IDH mutation (14:24)
Duration of therapy and long-term outcomes with
venetoclax/azacitidine; clinical research on combination therapy
with venetoclax and oral hypomethylating agents (HMAs) (23:08)
Treatment options for patients with AML who experience disease
progression on venetoclax/azacitidine; use of IDH inhibitors for
AML (29:23)
Case: A woman in her mid-50s with a complex medical history is
diagnosed with AML and receives 7 + 3 chemotherapy and gemtuzumab
ozogamicin (34:24)
Case: A man in his early 70s with AML and a FLT3-ITD mutation
receives 7 + 3 chemotherapy and midostaurin (47:36)
Optimal approach to the management of AML with FLT3 mutations
(51:20)
Impact of COVID-19 on the clinical care of patients with AML
(57:37)
Case: A man in his early 70s with AML with
myelodysplasia-related changes and mutations in RUNX1, SRSF2, ASXL1
and IDH2 receives liposomal daunorubicin and cytarabine (CPX-351)
followed by enasidenib (1:07:10)
Activity and tolerability of CPX-351 for AML; patient selection
(1:11:19)
Choice between a venetoclax/HMA combination and an IDH
inhibitor for patients with progressive AML and an IDH mutation
(1:17:53)
Feasibility and efficacy of stem cell transplantation in
patients with relapsed AML; use and tolerability of glasdegib and
low-dose cytarabine for AML (1:25:52)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.